Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study

Matti, Bassam Francis; Alwan, Alaa Fadhil

doi:10.4274/tjh.2012.0135

Cited by 12 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was slight male predominance in this study which was concordant with the results of other Iraqi studies [16], [17], [22], and with Turkish results [19].…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase

Alqasim

Obaid

Yaseen

et al. 2019

Leukemia Research Reports

Self Cite

View full text Add to dashboard Cite

Background Tyrosine kinases are highly expressed in platelets and play an important role in their activation process. Some studies have reported the blocking effects of tyrosine kinase inhibitors on different platelet functions. Objectives Evaluate the effects of nilotinib on platelets aggregation in 42 patients with chronic phase of CML and correlate the results with clinical and hematological parameters: age, complete blood count and presentation. Patients and methods This study was conducted on 42 patients diagnosed as Chronic Phase of Chronic Myeloid Leukemia based on clinical, morphological and cytogenetic study. All patients were on Nilotinib treatment and were attending the National Center of Hematology in Baghdad. About 9 mL of venous blood sample were collected from each patient and control subjects, samples divided into 3 parts for complete blood count, platelet aggregation test and PT and aPTT. Results The mean age was 41.3 ± 1.7 (mean ± SEM) years old. M:F ratio of 1.2:1. Mean duration of nilotinib therapy(1.4 years). All patients had normal PT and aPTT. Only 16 (38%) patients had abnormal aggregation response to epinephrine, but there was no statistically significant differences with control group. Conclusion Nilotinib had no adverse effect on platelet function nor patients clotting tests.

show abstract

“…There was slight male predominance in this study which was concordant with the results of other Iraqi studies [16], [17], [22], and with Turkish results [19].…”

Section: Discussionsupporting

confidence: 93%

“…These results comparable to other Iraqi studies done in 2013 and 2012 [16], [17]. Similar results were also reported in Saudi Arabia study [18].…”

Section: Discussionsupporting

confidence: 92%

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase

Alqasim

Obaid

Yaseen

et al. 2019

Leukemia Research Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sex, age, marital status, occupation and education level were similar between the cytopenia and no cytopenia groups and they did not increase the odds of developing cytopenia. A study carried out in Iraqi reported that females on imatinib had a predilection for anemia compared to males (20). This higher likelihood is probably due to the lower level of hemoglobin found in females at baseline compared to males (21).…”

Section: Discussionmentioning

confidence: 99%

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study

McLigeyo

Rajab

Oyiro

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Imatinib is the gold standard for the treatment of all phases of Philadelphia positive Chronic Myeloid Leukemia (CML). During treatment, patients may develop cytopenia. We aimed to study the baseline characteristics and factors associated with cytopenia at a Nairobi Hospital. Methods This was a retrospective case-control study of patients aged ≥ 18 years on follow-up at the Glivec International Patient Access Program (GIPAP) clinic from 2007–2015. The cases consisted of CML patients on imatinib who developed cytopenia. The controls were CML patients on imatinib who did not develop cytopenia. Baseline socio – demographic, clinical, hematologic, and molecular data were retrieved from patients’ files. Chi square or fishers’ exact tests were used to analyze for differences between cytopenia and no cytopenia. Binary logistic regressions were employed to identify relationships. Univariate and multivariate analyses were done to identify independent predictors of cytopenia. Odds ratios (OR) were presented including the 95% confidence intervals and respective p values. Results A total of 201 patients were studied. Males were 52%, 42% were aged 36–50 years, 70% had symptoms for > 12 months before diagnosis, 78.6% had B symptoms at baseline, 80% had a moderate splenomegaly at baseline, 40% and 37.4% developed cytopenia within 3 months and 3–6 months respectively after imatinib initiation. Baseline neutrophilia, neutropenia, anaemia, thrombocytosis, thrombocytopenia was found in 68%, 11%, 11%, 23.5% and 11% respectively. Baseline hemoglobin, neutrophil and platelet level were significantly different between the cytopenia and the no cytopenia group. On univariable analysis, baseline anemia with hb < 7.9g/dL (p = 0.002), neutropenia (p = 0.001), neutrophilia > 100,000/mm3 (p = 0.002) and thrombocytopenia (p = 0.001) increased the odds of developing cytopenia. On multivariable analysis, baseline anaemia (p value < 0.002), neutropenia (p value < 0.001), thrombocytopenia (p value, < 0.001) and thrombocytosis (p value, 0.033) increased the odds of developing cytopenia. Conclusion Odds of cytopenia were higher in presence of baseline cytopenia and thrombocytosis. Clinicians should have a high index of suspicion for these patients.

show abstract

“…Neutropenia developed in 33%, thrombocytopenia in 18%, and anemia in 6% of the patients [8]. In contrast, a study conducted in Indonesia reported lower levels of cytopenia with anemia at 20%, thrombocytopenia at 14%, and neutropenia at 4% [14] while a study from Iraqi documented anemia at 14%, and neutropenia and thrombocytopenia at 10% and 4% [15]. Lower proportions of cytopenia reported in some studies may be due to the analysis of patients with grade 3 and 4 cytopenia only.…”

Section: Discussionmentioning

confidence: 99%

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course

McLigeyo

Rajab

Ezzi

et al. 2020

Advances in Hematology

View full text Add to dashboard Cite

Background. Imatinib mesylate is the gold standard for the treatment of all phases of Philadelphia-positive chronic myeloid leukemia. Patients on imatinib treatment may develop cytopenia due to drug toxicity. This study aimed to determine the types, grades, and time course of cytopenia in CML patients on imatinib at a Nairobi hospital. Methods. This was a cross-sectional descriptive study of adult patients aged ≥18 years followed up at the Glivec International Patient Access Program (GIPAP) clinic from 2007 to 2015. Patients who developed cytopenia within 12 months of initiating imatinib were eligible. Clinical and hematologic data were retrieved from the patients’ charts and entered into a study proforma. Measures of central tendency such as mean, median, mode, standard deviation, and variance were used for analysis. Results. Sixty three percent (63.6%) of the 94 patients developed a monocytopenia, with anemia seen in 34%, neutropenia in 27.6%, and thrombocytopenia in 8% of the 94 patients. Anemia plus neutropenia was the most common bicytopenia at 12.7%. Pancytopenia was seen in only 5 of the 94 patients. Most of the cytopenia was grades 2 and 3. Anemia was present at baseline while neutropenia and thrombocytopenia developed within 12 months of imatinib initiation. Anemia resolved during the first 12 months of therapy while neutropenia and thrombocytopenia resolved within 24–36 months of treatment. Conclusion. Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24–36 months after imatinib initiation.

show abstract

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study

Cited by 12 publications

References 23 publications

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course

Contact Info

Product

Resources

About